Pharmaron Beijing Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Pharmaron Beijing has a total shareholder equity of CN¥14.0B and total debt of CN¥5.4B, which brings its debt-to-equity ratio to 38.7%. Its total assets and total liabilities are CN¥23.6B and CN¥9.5B respectively. Pharmaron Beijing's EBIT is CN¥1.5B making its interest coverage ratio -3.4. It has cash and short-term investments of CN¥2.6B.
Anahtar bilgiler
38.7%
Borç/özkaynak oranı
CN¥5.43b
Borç
| Faiz karşılama oranı | -3.4x |
| Nakit | CN¥2.60b |
| Eşitlik | CN¥14.03b |
| Toplam yükümlülükler | CN¥9.54b |
| Toplam varlıklar | CN¥23.57b |
Son finansal sağlık güncellemeleri
Recent updates
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Fly 29% But Investors Aren't Buying For Growth
Sep 27
Pharmaron Beijing Co., Ltd. (SZSE:300759) Shares Could Be 22% Below Their Intrinsic Value Estimate
Sep 20Pharmaron Beijing Co., Ltd.'s (SZSE:300759) Intrinsic Value Is Potentially 69% Above Its Share Price
May 12Pharmaron Beijing Co., Ltd.'s (SZSE:300759) 27% Share Price Surge Not Quite Adding Up
Mar 04Pharmaron Beijing (SZSE:300759) Seems To Use Debt Quite Sensibly
Feb 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 300759's short term assets (CN¥7.1B) exceed its short term liabilities (CN¥4.2B).
Uzun Vadeli Yükümlülükler: 300759's short term assets (CN¥7.1B) exceed its long term liabilities (CN¥5.4B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 300759's net debt to equity ratio (20.2%) is considered satisfactory.
Borcun Azaltılması: 300759's debt to equity ratio has reduced from 48.6% to 38.7% over the past 5 years.
Borç Kapsamı: 300759's debt is well covered by operating cash flow (46%).
Faiz Kapsamı: 300759 earns more interest than it pays, so coverage of interest payments is not a concern.